Ignite Creation Date:
2024-05-06 @ 9:17 AM
Last Modification Date:
2024-10-26 @ 12:12 PM
Study NCT ID:
NCT02944123
Status:
COMPLETED
Last Update Posted:
2020-08-20
First Post:
2016-10-24
Brief Title:
Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome HOPE-TAILOR
Sponsor:
Dong-A University
Organization:
Dong-A University
Study Overview
Official Title:
An Open-label Randomized Prospective Study Exploring Half Dose of Prasugrel and Ticagrelor in Platelet Response After Acute Coronary Syndromes
Status:
COMPLETED
Status Verified Date:
2020-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
East Asian patients will be required optimal dose of newer P2Y12 inhibitors prasugrel or ticagrelor to determine the safer treatment and better outcome Whether lower dose of these regimens are more adequate for clinical practice in Korea is unclear Therefore the investigators aim to evaluate efficacy and safety of half dose of new oral P2Y12 inhibitors in Korean patients with acute coronary syndrome ACS undergoing percutaneous coronary intervention PCI
Detailed Description:
In recent years newer oral P2Y12 receptor blockers prasugrel or ticagrelor have been strong recommendations for management of patients with ACS undergoing PCI These drugs provided more profound inhibitory effects than clopidogrel which could lead to marked reduction in ischemic events with relatively increase in bleeding complication specific to low body weight especially in women and East Asian patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None